Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Direct Biologics LLC is active in the Biotechnology & Pharmaceuticals technology area, with a portfolio that currently includes 6 pending office actions. These actions are spread across 6 distinct examiners, meaning that each pending matter is being reviewed by a different individual. This distribution of 6 pending office actions across 6 distinct examiners suggests a diverse set of perspectives on the company's biological or pharmaceutical claims. The portfolio is also distributed across 5 distinct art units, which reflects the technical scope of the current filings.
The busiest examiner, NIEBAUER, RONALD T, is currently handling 1 busiest examiner pending office action. Given that the total number of pending office actions is 6, the workload is distributed such that no examiner dominates the prosecution landscape. The involvement of 5 distinct art units indicates that the patent office sees several different technical facets in the company's filings, requiring counsel to navigate various specialized examination groups. This distribution across 6 distinct examiners and 5 distinct art units necessitates a versatile prosecution approach, as the requirements in one art unit may differ from those in another.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §112 only | 1 (17%) |
| Double-patenting + other | 3 (50%) |
| No statute on record | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| MCCORMICK, CATHERINE LYNN | 1 | 50.0% | +42.5% |
| KIM, TAEYOON | 1 | 51.5% | +52.1% |
| AUDET, MAURY A | 1 | 50.1% | +23.9% |
| GOLDBERG, JEANINE ANNE | 1 | 45.8% | +40.8% |
| ROGERS, ERIC JASON | 1 | 57.4% | +32.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17427192 | METHODS AND COMPOSITIONS FOR DEVELOPING TARGET SPECIFIC EXOSOME AND GROWTH FACTOR PRODUCTS | GOLDBERG, JEANINE ANNE | 126d overdue |
| 18340765 | ORAL DELIVERY OF THERAPEUTIC MAMMALIAN CELLS | MCCORMICK, CATHERINE LYNN | 54d |
| 19370240 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | NIEBAUER, RONALD T | — |
| 17606514 | METHOD FOR THE TREATMENT OF PERIODONTAL DISEASE USING CHARACTERIZED MESENCHYMAL STEM CELL GROWTH FACTORS AND EXOSOMES | KIM, TAEYOON | — |
| 17432138 | ACELLULAR INTRAVENOUS INFUSION INCLUDING MESENCHYMAL STEM CELL GROWTH FACTORS AND EXOSOMES | AUDET, MAURY A | — |
| 17418342 | METHODS AND COMPOSITIONS FOR TREATING SKIN AND HAIR DISORDERS | ROGERS, ERIC JASON | — |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| 1658 | 1 |
| 1631 | 1 |
| 1654 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19370240 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | NIEBAUER, RONALD T | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Oct 27, 2025 |
| 18340765 | ORAL DELIVERY OF THERAPEUTIC MAMMALIAN CELLS | MCCORMICK, CATHERINE LYNN | 1638 | Other | Non-Final OA | 54d | Pending | Jun 23, 2023 |
| 17606514 | METHOD FOR THE TREATMENT OF PERIODONTAL DISEASE USING CHARACTERIZED MESENCHYMAL STEM CELL GROWTH FACTORS AND EXOSOMES | KIM, TAEYOON | 1631 | §103 | Final Rejection | — | Pending | Oct 26, 2021 |
| 17432138 | ACELLULAR INTRAVENOUS INFUSION INCLUDING MESENCHYMAL STEM CELL GROWTH FACTORS AND EXOSOMES | AUDET, MAURY A | 1654 | §112 | Final Rejection | — | Pending | Aug 19, 2021 |
| 17427192 | METHODS AND COMPOSITIONS FOR DEVELOPING TARGET SPECIFIC EXOSOME AND GROWTH FACTOR PRODUCTS | GOLDBERG, JEANINE ANNE | 1682 | §103§112DP | Non-Final OA | 126d overdue | Pending | Jul 30, 2021 |
| 17418342 | METHODS AND COMPOSITIONS FOR TREATING SKIN AND HAIR DISORDERS | ROGERS, ERIC JASON | 1638 | §102§103§112DP | Non-Final OA | — | Pending | Jun 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial